Rivaroxaban
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Rivaroxaban. Rivaroxaban is a factor Xa inhibitor. It has a rapid onset of action. It is non-inferior to warfarin. Fully referenced neurology checklist.
Characteristics
- Rivaroxaban is a factor Xa inhibitor
- It has a rapid onset of action
- It is non-inferior to warfarin
- Its excretion is 2/3 hepatic and 1/3 renal
Dose
Locked: subscribe to see this section.
Contrindications
Locked: subscribe to see this section.
Recommendations in stroke
Locked: subscribe to see this section.
Interactions
Locked: subscribe to see this section.
Complications
Locked: subscribe to see this section.
Switching to Warfarin from Rivaroxaban
Locked: subscribe to see this section.
Switching from Warfarin to Rivaroxaban
Locked: subscribe to see this section.
Management of bleeding: Andexanet alfa
Locked: subscribe to see this section.
Management of bleeding: other measures
Locked: subscribe to see this section.
References
- Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment if venous thrombo-embolism. Eur Heart J 2011; 32:1968-1976.
- Tendera M, Syzdol M, Parma Z. ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? Cardiol J 2012; 19:4-10.
- Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
- Haas S, Bode C, Norrving B, Turpie AG. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag 2014; 10:101-114.
- Carpenter E, Singh D, Dietrich E, Gums J. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. Ther Adv Drug Saf 2019; 10:2042098619888133.
- And 1 more. Subscribe to see the full list
